March 10, 2020 09:47 AM EDTUpdated March 11, 02:02 PM
Financing
Cell/Gene Tx

J&J's fa­vorite CAR-T de­vel­op­er, cur­rent­ly owned by a Chi­nese CRO, is lay­ing the ground­work for US IPO

Amber Tong

Gen­Script, the low-pro­file own­er of CAR-T dark horse Nan­jing Leg­end Biotech, is hatch­ing a plan to spin out its fa­mous sub­sidiary and shoot for a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Ear­ly bits of in vi­vo CAR-T hu­man da­ta emerge from biotech tri­als in Chi­na

Bris­tol My­ers to lay off over 500 work­ers in New Jer­sey

PTC's Hunt­ing­ton’s study suc­ceeds, but ac­cel­er­at­ed ap­proval un­cer­tain

Re­cur­sion cuts near­ly half of its pipeline, in­clud­ing its most ad­vanced pro­gram

J&J's eye dis­ease gene ther­a­py bo­ta-vec fails in Phase 3 tri­al

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times